Bailard
PLX icon

Bailard’s Protalix BioTherapeutics PLX Stock Holding History

Bailard’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$169K Hold
61,100
– – ﹤0.01% 728
2026
Q2 		$142K Buy
+61,100
New +$129K ﹤0.01% 749
2024
Q1 		– Sell
-68,100
Closed -$121K – 794
2023
Q4 		$121K Buy
+68,100
New +$106K ﹤0.01% 679

Other funds holding PLX

Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
IRAG
Investment Research & Advisory Group Atlanta, Georgia $337M AUM 19.8% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Bailard's PLX Position: Q3 2026 in Review

Bailard held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 61,100 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #728.

Bailard first reported a position in PLX in Q4 2023 and has held it in 3 quarters since. 11 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Bailard held 61,100 shares of Protalix BioTherapeutics worth $169K as of Q3 2026.
  • Bailard left its Protalix BioTherapeutics share count unchanged in Q3 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #728 holding.
  • Bailard first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 3 quarters since.
  • 11 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.